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Introduction
Insufficient microbial exposure during early age, for 
example, because human gut microbiota (GM) 
diversity is decreasing,1 may be hypothesized to 
induce predisposition for allergic, inflammatory, 
and autoimmune diseases2 due insufficient induc-
tion of oral tolerance.3 Forkhead box p3 (Foxp3+) 
CD25+ regulatory T cells (Tregs) play an important 
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Abstract
Early life immune gut microbiota contact is critical for regulatory T cell–mediated oral tolerance induction. We induced 
a mucosal integrity breach with low dextran sulfate sodium dose right after weaning in BALB/c mice along with a 
standard high dose to study the impact of increased gut microbiota lymphatic tissue contact on the thymus. Both doses 
increased gut permeability, which caused a short-term generalized thymic involution and regulatory T cell induction in 
the mesenteric lymph nodes, even in the absence of clinically apparent inflammation in the low-dose group. The thymic 
regulatory T cells resisted thymic involution. In the low-dose group, we found acutely altered gut mobilization patterns 
characterized by changed gut-homing marker CD103 expression on mesenteric lymph node CD4+ T cells as well as on 
mature CD8+ T cells and developing CD4−/CD8− thymocytes. Furthermore, CD218a (IL-18-receptor-a) expression was 
acutely decreased on both mature CD8+ T cells and regulatory T cells, while increased on the mesenteric lymph node 
CD8+ T cells, indicating a direct link between the thymus and the mesenteric lymph nodes with CD218a in a functional 
role in thymic involution. Acute and non-persisting regulatory responses in the mesenteric lymph nodes were induced 
in the form of a relative regulatory T cell increase. We saw no changes in total thymic regulatory T cells and thus the 
thymus does not seem to play a major role of in the regulatory immunity induced by increased gut microbiota lymphatic 
tissue contact around weaning, which in our study primarily was located to the gut.
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role in the suppression of gut mucosa auto-reactivity,4–9 
and interleukin (IL)-10 is a key immune-modulatory 
factor.10,11 Rodent studies point out a window of 
possible immunomodulation in either the post- 
partum12–14 or the post-weaning period.15 Antibiotic 
treatment in neonatal mice increases atopic disease 
severity,16 and germ-free (GF) conditions during 
the first weeks of life lead to maturation defects of 
gut-associated lymphoid tissues (GALTs) and the 
spleen and dysfunctional natural killer T cell 
(NKT) function.12,13 Furthermore, post-weaning 
GM inoculation in GF mice permanently alters 
immune functions.15
The mucin-feeding bacterium Akkermansia 
muciniphila with an abundance of up to 3% of the 
gut bacteria17 is protective against, for example, 
type 1 diabetes (T1D),18,19 inflammatory bowel dis-
ease (IBD),20 autism,21 and diet-induced obesity.22 
Previously, we developed a mouse model, in which 
a low dose of drinking water dextran sulfate sodium 
(DSS) is used as an artificial mucin degrader,23 
which increased the abundance of A. muciniphila 
and decreased the abundance of segmented fila-
mentous bacteria (SFBs).23 We also observed 
increased Tregs in the mesenteric lymph nodes 
(MLNs) and the spleen, and decreased natural killer 
(NK) and NKT cells, while colonic expression of 
Foxp3 and Il1a was twofold upregulated 25 days 
after treatment.23 Vancomycin lowers the incidence 
of T1D in newborn T1D-prone non-obese diabetic 
(NOD) mice, and it propagates both A. muciniphila 
and proteobacteria-carrying lipopolysaccharide 
(LPS), which is a microbial-associated molecular 
pattern (MAMP).19 LPS induces NFκB-mediated 
inflammation through Toll-like receptor 4.24 This 
increased MAMP-GALT contact in early life may 
have a long-term protective role. Early life low-
dose DSS treatment of NOD mice does not reduce 
the incidence of the T helper cell (Th) type 1 domi-
nated T1D,25 while it significantly reduces later life 
local acute tissue inflammation in the Th type 2 
dominated oxazolone IBD model.26 Therefore, fur-
ther elucidation of early life MAMP-GALT contact 
is needed. Previous studies on early life induction 
of regulatory immunity have focused on either the 
gut or the systemics, but also the thymus may have 
a role. Thymic development of lymphoid progeni-
tor cells through double negative CD4−CD8− (DN), 
double positive CD4+ CD8+ (DP), and single posi-
tive CD4+ CD8−/CD4−CD8+ (SP) thymocyte stages 
followed by positive and negative selection secures 
continuous release to the periphery of naïve effec-
tor T cells with central tolerance.27 Contrary to con-
ventional thymic selection, thymus-developed 
Tregs (tTregs) pass through agonist selection 
thereby acquiring suppressive actions over conven-
tional T cells, themselves having an intermediate 
affinity toward self-peptides.28–30 Peripheral Tregs 
(pTregs) develop separately induced from naïve 
peripheral CD4+ T cells which acquire Foxp3 and 
CD25 expressing Treg functionality.31–33 MLN-
induced pTregs homing to the colonic mucosa are 
critical for oral tolerance,9,34,35 but tTregs may act 
synergistically.36,37 High-dose DSS is frequently 
used to model IBD, which also increases both 
MAMP-GALT contact and gut permeability.38 
Recently, DSS-induced IBD has been linked to 
thymic involution and changes in thymocyte sub-
sets in mice,39–41 suggesting a thymus–gut axis in 
which gut immune responses affect thymic T cell 
development. Thymic involution has previously 
been linked to, for example, pregnancy, glucocorti-
coid treatment, stress, and sepsis.42–45
We, therefore, hypothesized that reduced post-
weaning mucosal integrity induced by a low dose 
of DSS in mice would cause increased gut per-
meability even if clinical colitis was absent and 
that this increase in the gut permeability would 
induce long-term gut regulatory immunity and 
central changes in thymocyte development, acti-
vation, and recruitment due to the direct thymic-
gut axis.
Materials and methods
The experiments were carried out in accordance 
with the EU Directive 2010/63/EU and approved by 
the Animal Experimentation Inspectorate, Ministry 
of Environment and Food, Denmark (license no. 
2012-15-2934-00256).
Animals
BALB/cAnNBomTac mice (Taconic, Lille Skensved, 
Denmark) were housed with aspen bedding (Tapvei/
Brogaarden, Lynge, Denmark), Enviro-dri nesting 
material, cardboard shelters, Mini Fun Tunnel, and 
aspen chew blocks (Brogaarden, Lynge, Denmark) 
in open type 3 cages with wire lids (Tecniplast/
Scanbur, Karlslunde, Denmark) at 21°C and lights 
on from 6 a.m. to 6 p.m., fed Altromin 1324 chow 
(Brogaarden) and watered with tap water except dur-
ing study treatment periods.
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Experimental design
Two experiments were performed (Figure 1(a)) 
with females (Experiment 1) or mixed gender in a 
gender-blocked randomization (Experiment 2). In 
each experiment, animals were randomized into 
three treatment groups. Based on earlier treatment 
protocols23,25,26,39,40,46 at 5 weeks of age, control 
group mice received regular tap water ad libitum 
throughout the experiment period, the low-dose 
group received 1.5% DSS (molecular weight of 
Figure 1. Effects of low- and high-dose dextran sulfate sodium (DSS) on gut permeability and cytokine expression in BALB/c mice 
(control, low dose (1.5%), and high dose (4%)). (a) Study timeline for Experiments 1 and 2. Serum FITC-Dextran concentrations on 
day 3 of treatment (b) and on day 2 after treatment (c), and for day 3 during treatment and day 2 after treatment in the high-dose 
groups (d). Mean colon cytokine concentrations IFN-γ (e), IL-1β (f), IL-6 (g), IL-10 (h), KC/GRO (i), and TNF-α (j) on day 1 (acute 
phase) and day 25 (long-term phase) after treatment. Group mean values and SEM are depicted on non-transformed data, except 
graphs (d) and (g) in which median and range are depicted due to non-Gaussian distribution of data. Graphs c, f, g, I, and j: statistics 
calculated on transformed data. Graph c: trend line for linear regression derived best fitted line depicted on graph (goodness of fit 
(r2) and P-value (slope ≠ 0) in box). Graph d: significance levels as calculated with Mann–Whitney U test.
*P ⩽ 0.05; ***P ⩽ 0.001; ****P ⩽ 0.0001.
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36.000–50.000; MP Biomedicals, Santa Ana, CA, 
USA), while the high-dose group received 4% DSS 
in regular tap water ad libitum for 7 days 
(Experiment 1: n = 6–8/group per time point; 
Experiment 2: n = 7–8/group or n = 5–6/group on 
day 3 of treatment and day 2 after treatment, 
respectively, based on power calculation on previ-
ous data23,25,26). Body weight (BW), food, and 
water intake were registered weekly. Humane end-
points (>20% loss of BW and/or decreased gen-
eral condition) were assessed daily during DSS 
treatment and the first 4 days after treatment, and 
hereafter, biweekly. Sacrifice time points were 
based on earlier studies.40 In Experiment 1, half of 
the mice were euthanized by cervical dislocation 
on day 1 and day 25 after treatment for collecting 
samples during the acute inflammation phase and 
in the long-term phase after healing in the 4% 
group. In Experiment 2, half of the mice were euth-
anized by cervical dislocation on day 3 during 
treatment and day 2 after treatment to evaluate gut 
permeability during and after treatment. Before 
euthanasia, animals were anesthetized with fenta-
nyl/fluanisone (Hypnorm; VetaPharma, Leeds, 
UK) and Midazolam (Dormicum, Roche, Denmark) 
diluted 1:1:2 in sterile water and retro-orbital blood 
samples were collected (Figure 1(a)).
Clinical scoring
Clinical scoring47,48 was performed to evaluate 
onset and extent of colon inflammatory develop-
ment. Colon length (distal from the cecum to anal 
opening without fecal content) and colon weight/
length ratio were determined to evaluate macro-
scopic colon changes from Experiment 1 mice. 
The disease activity index score to evaluate clinical 
colitis was determined for the 4% groups during 
treatment and the first 4 days after treatment. The 
score was based on daily evaluations of weight 
loss, stool consistency, occult blood in feces 
(Hemoccult SENSA; Beckman Coulter Inc., 
Atlanta, GA, USA), and general condition.48
Histology
Distal colon samples (approximately 2 cm sagittal 
half) from Experiment 1 mice were stored in 9 mL 
S-Monovette® tubes, filled with 4% formaldehyde 
solution (Enclosed Formalin System; Sarstedt AG 
& Co, Nümbrecht, Germany) and processed for 
hematoxylin and eosin staining. Inflammation and 
crypt scores were blindly evaluated.48 The sum of 
the crypt and inflammation scores was combined 
to a histological index score of microscopic 
pathology.
Flow cytometry
MLN and thymus from Experiment 1 mice were 
stored in Eppendorf tubes containing 1 mL Hanks’ 
balanced salt solution (Hanks’) (A1711; AppliChem, 
St. Louis, MO, USA) at 5°C. Cells were isolated 
from the thymus and MLN shortly after organ col-
lection by squeezing fresh organs between two 
microscope slides, resuspending in Hanks’, and sub-
sequently filtering through a 70-µm cell strainer. 
The total amounts of thymocytes were calculated 
after counting in a hemocytometer. The filtered cell 
suspensions were kept cold for the remainder of the 
preparation, centrifuged, and re-suspended in phos-
phate buffered saline (PBS) (Sigma-Aldrich, St. 
Louis, MO, USA) with 2% fetal bovine serum. 
Approximately, 4 million cells from each organ 
sample were transferred to a 96-well plate. Staining, 
for 30 min with surface marker antibodies, was used 
to distinguish different T cell populations. For 
nuclear staining of Foxp3 after surface staining, the 
cells were first fixated, permeabilized, and stained 
for intracellular Foxp3 according to the manufac-
turer’s protocol (eBioscience, San Diego, CA, 
USA). The flow cytometry analysis was performed 
with BD LSRFortessa™ analyzer (BD Biosciences, 
Franklin Lakes, NJ, USA). The following mouse 
antibodies were utilized in the flow cytometry anal-
ysis: fluorescein isothiocyanate (FITC)-conjugated 
mAbs-recognizing CD103 (2E7) (eBioscience); 
phycoerythrin-conjugated mAbs-recognizing Foxp3 
(FJK-16s; eBioscience); phycoerythrin-CF594- 
conjugaged mAbs-recognizing T cell receptor 
(TCR) γδ (GL3); phycoerythrin-cyanin7-conju-
gated mAbs-recognizing CD8α (53-6.7); Alexa 
Fluor 647–conjugated mAbs-recognizing CD218a 
(BG/IL-18RA); Alexa Fluor 600–conjugated mAbs-
recognizing CD4 (RM4-5); Brilliant Violet 
421–conjugated mAbs-recognizing CD314 (CX5; 
Biolegend, San Diego, CA, USA); allophycocya-
nin-cyanin7-conjugated mAbs-recognizing CD44 
(IM7); Brilliant Violet 605–conjugated mAbs-rec-
ognizing CD3 (17A2); Brilliant Violet 711–conju-
gated mAbs-recognizing TCRβ (H57-597); and 
Brilliant Violet 786–conjugated mAbs-recognizing 
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CD25 (PC61); all antibodies were from BD 
Biosciences unless otherwise stated.
The output was analyzed with FlowJo v10 (Tree 
Star Inc., San Carlos, CA, USA) (detailed gating 
strategies in Supplemental Figures S1 and S2).
Cells were stained for relevant identification 
markers and phenotypic markers: CD103, 
CD218a, CD314, CD44, and CD25. All cell sam-
ples were initially gated for size and removing of 
doublets (FSC-A/FSC-H). Time-axis gating 
removed air bubble interference in a few of the 
samples (eight MLN samples on day 1  after treat-
ment, five MLN samples on day 25  after treat-
ment, and one thymus sample on day 1  after 
treatment). The thymocyte sample was included in 
the percentage although excluded from the statisti-
cal analysis of the total number of thymus cells. 
Thymocytes were gated for CD4 and CD8α to 
identify different thymocyte subsets. SP CD4+ 
TCRαβ+ thymocytes and SP CD8+ TCRαβ+ thy-
mocytes were identified. tTreg cells were identi-
fied from the SP CD4+ TCRαβ+ thymocyte 
population by their co-expression of Foxp3 and 
CD25. Finally, DN thymocytes were identified by 
lacking CD4, CD8α, TCRβ, and TCRγδ expres-
sion. Brilliant Violet 786 emission of the CD25-
mAb in the DN population was too high to properly 
compensate. This was solved by adjusting the gat-
ing strategy to encompass the high emission. The 
DN1-DN4 subsets were further divided by their 
expression of CD25 and CD44; DN1 (CD25− 
CD44+), DN1-2 (CD25(int) CD44+), DN2 
(CD25(high) CD44+), DN3 (CD25+ CD44−), and 
DN4 (CD25− CD44−). MLN cells were gated for 
TCRαβ and TCRγδ to identify TCRαβ+ cells in 
the dump gate. CD8+ TCRαβ+ and CD8+ 
TCRαβ+ T cells were identified within the 
TCRαβ+ gate. Foxp3+ CD25+ regulatory T cells 
and CD103+ CD4+ T cells were identified within 
the CD4+ TCRαβ+ gate, and finally, Foxp3+ 
CD25+ regulatory T cells within the CD103+ 
CD4+ TCRαβ+ gate. The frequency of the lym-
phocyte gate was utilized to calculate the total thy-
mocyte counts for each subset.
Colon cytokine measurements
The distal colonic samples (approximately 2 cm 
distal sagittal half) from Experiment 1 mice were 
stored in sterile 1 mL Eppendorf tubes at −80°C 
until preparation. Colon pieces were prepared by 
defrosting and homogenizing with an Ultra Turrax 
T8 in cold inhibitor buffer (10 mg tissue to 100 µL 
buffer) consisting of MSD Tris Lysis buffer (cat. 
no. R60TX-3; MSD, Rockville, MD, USA) and 
enzyme inhibitors from the MSD inhibitor pack 
(cat. no. R70AA-1, MSD) (mix: 10 mL Tris lysis 
buffer; 100 µL phosphatase inhibitor 1; 100 µL 
phosphatase inhibitor 2; 200 µL protease inhibi-
tor). After homogenization, the samples were left 
at 5°C in a refrigerator for 20 min, before centrifu-
gation (7500 r/min, 5 min, 5°C), removal of the 
supernatant to clean Eppendorf tubes and storage 
at −80°C until the inflammatory cytokines inter-
feron (IFN)-γ, IL-10, IL-12p70, IL-1β, IL-2, IL-4, 
IL-5, IL-6, keratinocyte chemoattractant/growth-
regulated oncogene (KC/GRO), and tumor necro-
sis factor (TNF)-α, were measured with the 
V-PLEX Proinflammatory Panel 1 (mouse) Kit 
multiplex immunoassay (cat. no. K15048D-2, 
MSD), as recommended by the manufacturer. All 
plates were analyzed utilizing a Sector Imager 
(MSD).
FITC-Dextran assay
FITC-Dextran (average molecular weight: 3000–
5000; Sigma-Aldrich) was dissolved in PBS 
(Sigma-Aldrich) with 125 mg/mL. Experiment 2 
mice were fasted 6 h and gavaged with FITC-
Dextran (600 mg/kg). Precisely 2 h after dosing, 
retro-orbital blood samples were collected into 
sterile Eppendorf tubes using sodium heparin hem-
atocrit tubes. Blood samples were centrifuged 
(4°C, 8000g, 7 min), and serum was transferred to 
clean Eppendorf tubes and diluted 1:1 with PBS. 
Two independent standard curves were prepared 
by utilizing diluted serum (1:1 with PBS) from 
PBS sham dosed (orally) mice. Stock FITC-
Dextran (125 mg/mL) was mixed in diluted serum 
to a concentration of 0.008 mg/mL and serially 
diluted 1:2 with diluted serum to a concentration of 
1.25 × 10–4 mg/mL. Pure diluted serum was uti-
lized as a zero concentration. Samples were plated 
in 100 µL triplets or duplets, and standard curves 
were plated on a black 96-well microplate. The 
concentration of FITC-Dextran in serum was deter-
mined by a spectrophotometric fluorometry plate 
reader (excitation 485 nm, emission wavelength 
535 nm).
6 European Journal of Inflammation
Statistics
All rawdata output from experiments used for sta-
tistical analysis can be found in supplementary 
table 5. Normality and variances were evaluated 
with d’Agostino–Pearsson test, Brown–Forsythe 
test, or F-test. Parametric data were achieved by 
transformations when appropriate, and differ-
ences between group mean values evaluated with 
one-way analysis of variance (ANOVA) with 
Tukey’s multiple comparisons or Student’s t-test 
with P-values ⩾ 0.05 considered significant. 
Non-parametric data were evaluated with 
Kruskal–Wallis along with Dunn’s multiple com-
parisons test, or the Mann–Whitney U test. 
Correlations between the DSS treatment doses 
and thymocytes or MLN T cells were analyzed 
with linear regression if observing trends of a 
dose correlation. Four MLN cell samples (one in 
1.5% DSS group and three in 4% DSS group, day 
1 after treatment) were excluded from statistical 
analysis due to extensive cell death.
Results
DSS increased gut permeability and induced an 
inflammatory state without morphological colitis 
in the low-dose (1.5%) group
On day 2  after treatment, FITC-Dextran assay, 
during and shortly after DSS treatment, showed a 
linear positive dose response in gut permeability 
(Figure 1(b)–(d)). The combination of the histo-
logical index, colon length, and weight/length ratio 
did not indicate macroscopic or microscopic colitis 
in the 1.5% group at any time, apart from a signifi-
cantly lower colon length than the control group on 
day 1  after treatment (P ⩽ 0.05). Colitis was 
observed in the 4% group acute on day 1  after 
treatment, as the histological index, colon length, 
and weight/length all differed significantly from 
the control group (P ⩽ 0.0001; P ⩽ 0.01; and P ⩽ 
0.0001, respectively), as known for acute colitis.46 
On day 25  after treatment, a chronic colitic state 
was still observed in the 4% group with a signifi-
cantly higher histological index than the control 
group (P ⩽ 0.05). The disease activity index score 
indicated that clinical colitis started on day 5 dur-
ing treatment with symptom severity increasing 
until day 2 after treatment, whereafter it started 
subsiding. BW, food intake, and water intake 
registrations correlated with the clinical scoring 
(Supplemental Figures S3 and S4).
Cytokine responses in the low-dose (1.5%) 
group were comparable to the control group
In the 1.5% group, no cytokine levels differed sig-
nificantly from the control group at any time. The 
levels of pro-inflammatory cytokines in the 4% 
group IL-1β (P ⩽ 0.001), IL-6 (P ⩽ 0.0001), TNF-
α (P ⩽ 0.0001), IL-10 (P ⩽ 0.001), and KC/GRO 
(P ⩽ 0.001) were significantly higher in the colon 
compared to both other groups on day 1  after treat-
ment (Figure 1(e)–(j)), which is comparable to 
other studies.46,49–51 Furthermore, IFN-γ was sig-
nificantly higher in the 4% group on day 1  after 
treatment compared to the 1.5% group (P ⩽ 0.05). 
As the significant differences in both IFN-γ and 
IL-10 between the dosing groups were small, these 
may have less biological relevance. Compared to 
day 1  after treatment, all above-mentioned 
cytokines reduced significantly in the 4% group on 
day 25  after treatment (IFN-γ, P ⩽ 0.05; IL-6, P ⩽ 
0.01; IL-10, P ⩽ 0.05; KC/GRO, P ⩽ 0.0001; and 
TNF-α, P ⩽ 0.001), with exception of IL-1β, which 
remained significantly higher compared to both the 
other groups on day 25  after treatment (both P ⩽ 
0.01). IL-5 and IL-12p70 concentrations did not 
differ between groups at any time.
Increased permeability caused mild generalized 
acute thymic involution
To evaluate thymocyte differentiation changes and 
possible thymic involution, the total number of thy-
mocytes and all major subsets were estimated and 
analyzed. A general trend showed a mild degree of 
acute thymic involution on day 1  after treatment in 
both cortical and medullary subsets of the thymus 
and a negative correlation between DSS dose and 
the total number of thymocytes (Figure 2(a)).
Thymocyte subset distribution was similarly 
indicating the same stress level in all three groups 
(Figure 2(b)–(d)). The thymic involution on day 1 
after treatment was mirrored in early developmen-
tal DN1, DN1-2, DN3, and DN4 thymocyte sub-
sets displaying linear negative dose responses, 
which all were significantly lower in the 4% group 
compared to the control group (all P ⩽ 0.01). A 
lower amount of thymocytes in the DN1, DN1-2, 
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and DN4 subsets was also observed between the 
control and 1.5% groups (all P ⩽ 0.05) (Figure 
2(e), (f), (h), and (i)). Apart from a general trend of 
negative linear dose-response, there were no single 
linear correlations or significant differences in the 
DN2 or DP thymocyte subsets on day 1  after treat-
ment (Figure 2(g) and (j)). Significantly less mature 
SP CD8+ subset thymocytes were found in both 
the 1.5% and 4% groups compared to the control 
group (P ⩽ 0.05 and P ⩽ 0.001, respectively). 
Both SP CD4+ and SP CD8+ thymocyte displayed 
linear negative dose responses, but no significant 
differences were found between groups in the 
mature SP CD4+ thymocytes indicating a stronger 
impact on the SP CD8+ subset (Figure 2(k) and 
(l)). Finally, no significant correlations or differ-
ences were found in the total thymocyte counts of 
the Foxp3+ CD25+ Treg thymocytes (Figure 2(m)). 
Figure 2. Thymocyte counts after low-dose (1.5%) and high-dose (4%) dextran sulfate sodium (DSS) treatment in BALB/c mice. 
(a) Total thymocyte count on day 1 after treatment. Thymocyte subset distribution day 1 after treatment for the control group 
(b), the 1.5% group (c), and the 4% group (d). Total thymocyte counts in the three treatment groups on day 1 after treatment for 
the thymocyte subsets double negative (DN1) (e), DN1-2 (f), DN2 (g), DN3 (h), DN4 (i), DP (j), single positive (SP) CD8+ (k), SP 
CD4+ (l), and Foxp3+ CD25+ regulatory T cells (Tregs) (m). Group mean values and SEM are depicted on non-transformed data. 
Trend line for linear regression derived best fitted line depicted on graphs if significant (Goodness of fit (r2) and P-value (slope ≠ 0) 
in box).
*P ⩽ 0.05; **P ⩽ 0.01; ***P ⩽ 0.001.
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Interestingly, a reversal of the acute thymus invo-
lution was observed with no differences in counts 
of total thymocytes of individual subsets between 
treatment groups on day 25  after treatment.
Increase in the permeability increased Foxp3+ 
CD25+ Treg cell numbers transiently in the 
MLNs, but not in the thymus
Analyzing the frequencies of Foxp3 and CD25 co-
expression on SP CD4+ thymocytes and MLN 
CD4+ T cells showed that in the thymus Foxp3+ 
CD25+ tTreg, cells were relatively unaffected by 
the treatment (Figure 3(a) and (b)). In the MLN, 
the Foxp3+ CD25+ Treg cells showed a linear pos-
itive dose response on day 1  after treatment, and 
the expression in the 1.5% and 4% groups was sig-
nificantly higher compared to the control group 
(both P ⩽ 0.05). The effects were absent on day 25 
after treatment, indicating a normalization of the 
cell population homeostasis at this time point in the 
MLN (Figure 3(c) and (d)).
Increase in the permeability changed thymocyte 
and MLN T cell gut-homing
To assess how DSS treatment changes gut-homing, 
CD103 expression52–55 was analyzed on the differ-
ent thymocyte and MLN T cell subsets. CD103+ SP 
CD8+ thymocytes expressed a linear positive dose-
related response on day 1  after treatment, however 
without significant differences between groups 
(Figure 4(a)).
Conversely, the CD103+ DN2 thymocytes 
expressed a linear negative dose-response on day 
1  after treatment with small but significantly 
lower expression in the 1.5% and 4% groups 
compared to the control group (P ⩽ 0.01 and P ⩽ 
0.001, respectively) (Figure 4(d)). MLN CD4+ T 
cells expressed a minor but significant (P ⩽ 0.05) 
increase in the CD103 from 1.97% in the control 
group to 2.36% in the 1.5% group on day 1  after 
treatment (Figure 4(f)). As most CD103 express-
ing CD4+ T cells also expressed Foxp3 and CD25 
(mean group expressions between 72.59% and 
Figure 3. Foxp3 expression on thymus and mesenteric lymph node (MLN) T cells after low-dose (1.5%) and high-dose (4%) 
dextran sulfate sodium (DSS) treatment in BALB/c mice. Co-expression (%) of regulatory T cell (Treg) markers Foxp3 and CD25 
on single positive (SP) CD4+ thymocytes day 1 (a) and day 25 after treatment (b). Co-expression (%) of Treg markers Foxp3 and 
CD25 on CD4+ T cells in the MLN on day 1 (c) and day 25 after treatment (d). Group mean values and SEM are depicted on non-
transformed data. Trend line for linear regression derived best fitted line depicted on graphs if significant (goodness of fit (r2) and 
P-value (slope ≠ 0) in box).
*P ⩽ 0.05.
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80.77%), the majority of the gut-homing CD4+ T 
cells were Tregs. Furthermore, a linear positive 
dose response in the co-expression of the Treg 
cell markers Foxp3 and CD25 was found on the 
subset. Significantly higher co-expression of 
Foxp3 and CD25 Treg cell markers on gut-hom-
ing CD4+ T cells in the 4% group compared to 
the control group on day 1 after treatment (P ⩽ 
0.05) was also observed. Overall, this indicates 
an increase in the Tregs in the gut-homing CD4+ 
T cell subset of the MLN (Figure 4(h)). No other 
changes in CD103+ expression were observed on 
any thymocyte or MLN T cell subset at any time 
point.
Figure 4. Gut-homing and activation marker expression on thymocyte and mesenteric lymph node (MLN) T cell subsets after 
low-dose (1.5%) and high-dose (4%) dextran sulfate sodium (DSS) treatment in BALB/c mice. The CD103 expression (%) is depicted 
in the single positive (SP) CD8+ (a), SP CD4+ (b), Foxp3+ CD25+ regulatory T cells (Treg) (c), and double negative (DN2) (d) 
thymocyte subsets day 1 after treatment. The CD218a expression (%) is depicted in the SP CD8+ (i), SP CD4+ (j), Treg (k), and 
DN1-2 (l) thymocyte subsets day 1 after treatment.  The CD103 expression (%) is depicted in the CD8+ (e), the CD4+ (f), and 
the Treg (g) MLN T-cell subsets, and co-expression (%) of Foxp3 and CD25 is also depicted on the CD103+ CD4+ (h) MLN T 
cells on day 1 after treatment. The CD218a expression (%) is depicted in the CD8+ (m), the CD4+ (n), and the Treg (o) MLN 
T cells on day 1 after treatment, and in the CD4+ MLN T cells on day 25 after treatment (p). Group mean values and SEM are 
depicted on non-transformed data in each graph. Trend line for linear regression derived best fitted line depicted on graphs if 
significant (goodness of fit (r2) and P-value (slope ≠ 0) in box).
*P ⩽ 0.05; **P ⩽ 0.01; ***P ⩽ 0.001.
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Increase in the permeability changed activation 
of several thymocytes subsets and T cell 
subsets in MLN
To assess how DSS treatment changed activation, 
the marker CD218a and the co-stimulatory 
marker CD31456–58 were analyzed on the differ-
ent thymocyte and MLN T cell subsets. SP CD8+ 
thymocytes, Foxp3+ CD25+ tTregs, and the 
DN1-2 subsets expressed a negative linear dose 
response of CD218a. On day 1  after treatment, a 
significant reduction in CD281a expression was 
observed for all three subsets in the 4% group 
compared to the control group (P ⩽ 0.001, P ⩽ 
0.05, and P ⩽ 0.01, respectively). A similar 
reduction was observed for the SP CD8+ thymo-
cytes in the 1.5% group compared to the control 
group (P ⩽ 0.01). Relatively small decreases in 
the CD218a expression were observed on SP 
CD8+ thymocytes and Foxp3+ CD25+ tTregs. 
However, a relatively large decrease from a mean 
expression of 44.13% in controls to 27.73% in 
the 4% group was observed in the DN1-2 subset 
(Figure 4(i), (k), and (l)). At no time point were 
changes in CD218a expression observed on the 
SP CD4+ (Figure 4(j)) or other thymocyte sub-
sets. Interestingly, in the MLN T cells, a linear 
positive dose response was observed in the 
CD218a expression on CD8+ T cells on day 1 
after treatment, along with significantly higher 
expression in the 4% group compared to the con-
trol and 1.5% groups (P ⩽ 0.01 and P ⩽ 0.05, 
respectively). No differences in CD218a expres-
sion were observed in the CD4+ T cells or Foxp3+ 
CD25+ Treg cells of the MLN on day 1 after 
treatment (Figure 4(m)–(o)). Interestingly, the 
MLN CD4+ T cells of the 4% group expressed 
significantly more CD218a compared to the 1.5% 
group on day 25  after treatment, indicating a 
delayed response (Figure 4(p)). The increased 
activation of MLN CD8+ T cells on day 1  after 
treatment was also observed as a positive dose 
response in expression of the co-stimulatory 
marker CD314 (r2 = 0.3356, P ⩽ 0.05) along 
with minor but significantly higher expression in 
the 4% (0.47%) compared to the control group 
(0.15%) (P ⩽ 0.05). A positive linear dose 
response in CD314 expression was also observed 
in the MLN CD4+ T cells (r2 = 0.3553, P ⩽ 0.01) 
and Treg T cells (r2 = 0.2787, P ⩽ 0.05), along 
with significantly increased expression in the 4% 
compared to the control groups (P ⩽ 0.05) of 
CD4+ T cells. Furthermore, a positive dose 
response in CD25 and CD44 expression on CD4+ 
T cells in the MLN (r2 = 0.4270, P ⩽ 0.01) was 
observed on day 1  after treatment along with sig-
nificantly increased expression in both the 1.5% 
and the 4% groups compared to the control group 
(P ⩽ 0.01 and P ⩽ 0.05, respectively). No other 
relevant differences between groups were found 
on any thymocyte subsets or MLN T cell subsets 
on day 1 or day 25  after treatment.
Changed CD103 and CD218a expressions are 
correlated to reduced total thymocyte counts
The total amount of SP CD8+ and DN2 thymo-
cytes expressing CD103 and the amounts of SP 
CD8+, Treg, and DN1-2 thymocytes expressing 
CD218a on day 1  after treatment were analyzed to 
evaluate if changed expression of these markers 
were also reflected in the total thymocyte counts 
(Table 1). A negative dose response was found in 
the total thymocyte counts of CD103 expressing 
SP CD8+ and DN2 thymocyte subsets on day 1 
after treatment, as reflected by significantly 
decreased counts in the 4% groups compared to the 
control group for both subsets (P ⩽ 0.01 and P ⩽ 
0.05, respectively). There were significantly fewer 
CD103+ expressing DN2 thymocytes in the 1.5% 
compared to the control group (P ⩽ 0.05). A 
ROUTs test (Q = 1%) identified outlier (with a 
total thymocyte count of 1,440,000) was removed 
from the control group when analyzing the CD103+ 
DN2 subset. The total thymocyte counts of CD218a 
expressing SP CD8+, tTreg, and DN1-2 thymo-
cytes were all significantly decreased compared to 
the control group in both the 1.5% group (P ⩽ 
0.01, P ⩽ 0.01, and P ⩽ 0.05, respectively) and the 
4% group (P ⩽ 0.001, P ⩽ 0.01, and P ⩽ 0.001, 
respectively). Negative dose responses were also 
identified for all three subsets. This shows that 
DSS decreases the number of thymocytes express-
ing CD218a.
Discussion
As previously described,23,25,26 post-weaning oral 
DSS treatment increased gut permeability in mice. 
While active colitis was absent in the 1.5% group, 
the 4% dose induced both macroscopic and micro-
scopic acute colitis, and acute pro-inflammatory 
cytokine increases indicative of an immune 
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response due to increased microbial antigen bur-
dens.46,49,50 This progressed to chronic pathology 
with CD218a expression on CD4+ T cells and a 
persisting increase in the colon levels of IL-1β, as 
known for colitis.59–61 DSS treatment increased gut 
permeability, which as hypothesized induced a 
short-term generalized thymic involution in both 
groups. tTregs resisted the thymic involution, but 
the changed expression of gut-homing marker 
CD103 on mature SP CD8+ and DN2 thymocytes 
along with CD4+ MLN T cells indicated acute cell 
mobilization to the gut. Activation expressed by 
CD218a was found to acutely decrease on SP 
CD8+, Tregs, and DN1-2 thymocytes while simul-
taneously increasing on MLN CD8+ T cells. The 
overall similar relative thymocyte subset distribu-
tion in all three groups indicates that changes 
observed were DSS-induced and not a stress-
induced thymic involution.
Acute colitis has previously been linked to 
thymic involution,39,41,62 and it has been suggested 
to lead to a combination of both increased thymo-
cyte apoptotic rates and increased T cell release to 
the periphery.41,63,64 We show that thymic involu-
tion occurs even in the lack of colon inflammation. 
Interestingly, we found that different thymocyte 
populations seem to respond differently to gut sig-
nals with a more pronounced decrease in the SP 
CD8+ compared to SP CD4+ thymocytes. This 
suggests that an increased GM–host contact acutely 
leads to a higher migration of naïve CD8+ T cells 
than CD4+ T cells to the gut, which may also be an 
indication of increased GM–host contact.65 The 
observed changes in functional traits of both med-
ullary and cortical thymocyte subsets may indicate 
increased naïve T cell release from the thymus to 
the periphery due to increased permeability and 
GM-host interaction. The gut-homing marker 
CD103 plays a functional role in thymocyte devel-
opment,66 and the increase in the CD103 expres-
sion on SP CD8+ thymocytes might reflect 
expanded proliferation and naïve CD8+ T cell 
release to the periphery.67 Acutely increased CD103 
expression on SP CD8+ thymocytes along with 
decreased numbers of the subset could, therefore, 
indicate increased proliferation and CD8+ T cell 
release. Some commercial barrier bred mice lack 
CD8+ T cells,68 which in the light of our findings 
may be due to the lacking early life bacterial stimu-
lation. Peaudecerf et al.69 showed that unconven-
tional intraepithelial lymphocytes (IELs) are able 
to leave the thymus during the DN1-2 and DN2 
stage of thymus development via an alternative 
pathway. As both the CD103 expression level on 
DN2 thymocytes and total numbers of the subset 
were acutely decreased, this could indicate at a 
peripheral release of these thymocytes, potentially 
via this alternative pathway, to the gut intraepithe-
lial lymphocyte compartment. However, more 
studies are needed to investigate if this is a DSS/
gut-specific phenomenon.
Activated CD218a expressing thymocytes in 
vitro and in vivo can be stimulated with IL-12 and 
IL-18 to increase apoptotic rates and production of 
IFN-γ.70 Across several thymocyte subsets, such as 
SP CD8+, DN1-2, and Treg thymocytes, decreased 
CD218a expression was observed during acute 
thymic involution. The decreased CD218a expres-
sion on SP CD8+ thymocytes along with decreased 
numbers of this subset coinciding with an increase 
in the marker expression on CD8+ T cells in the 
MLN is especially interesting, as this may point at 
an increased release of CD218a expressing thymo-
cytes to the periphery rather than involution due to 
increased apoptosis. Future studies may determine 
whether CD218a is a potential marker for thymic 
Table 1. Total thymocyte counts for selected subsets on day 1 after dextran sulfate sodium (DSS) treatment in BALB/c mice.
Thymocyte subset Mean (SD) (106 thymocytes) Linear regression
Control group 1.5% DSS group 4% DSS group Slope ± SE (106 cells) r2 P-value
CD103+ single positive CD8+ 9.477c (3.270) 6.289 (1.922) 4.547a (1.695) −1.208 ± 0.338 0.4018 0.0020
CD103+ double negative 2 0.015b,c (0.008) 0.007a (0.003) 0.005a (0.003) −0.002 ± 0.001 0.3071 0.0112
CD218a+ single positive CD8+ 0.071b,c (0.030) 0.030a (0.014) 0.016a (0.006) −0.013 ± 0.003 0.5127 0.0003
CD218a+ regulatory T cell 0.127b,c (0.043) 0.070a (0.012) 0.058a (0.020) −0.017 ± 0.004 0.4353 0.0011
CD218a+ double negative 1–2 0.023b,c (0.009) 0.012a (0.007) 0.006a (0.003) −0.004 ± 0.001 0.5046 0.0003
aP < 0.05 versus control group.
bP < 0.05 versus low-dose group (1.5% DSS group).
cP < 0.05 versus high-dose group (4% DSS group).
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involution and whether CD218a expression on SP 
CD8+, DN1-2, and Treg thymocytes is associated 
with gut immune responses. Although our study 
cannot reject a role of thymocyte apoptosis after 
DSS treatment, it indicates increased release of 
thymic CD218a+ CD8+ T cells migrating to the 
MLN, which again indicates a possible direct link 
between the thymus and MLN as a response to 
increased GM–host contact.
As the increased gut permeability only seemed to 
increase Foxp3+ CD25+ Treg numbers in the MLNs 
while not in the thymus, the MLN Foxp3+ CD25+ 
Treg increase may be due to increased induction of 
Foxp3+ CD25+ pTregs rather than migration of 
Foxp3+ CD25+ tTregs. Interestingly, increased gut 
permeability and the assumed subsequently 
increased GM–host contact seemed to increase the 
relative amount of Foxp3+ CD25+ Tregs in the gut-
homing MLN CD103+ CD4+ T cell subset. As no 
increase in CD103 expression was observed in MLN 
Tregs, de-novo-synthesized pTregs may be mobi-
lized rather than existing MLN Tregs. Furthermore, 
a relatively small but significant increase in the gut-
homing marker CD103 expression on MLN CD4+ 
T cells was also observed in mice treated with low-
dose DSS, that is, increased GM–host contact does 
induce an immunological response in which MLN 
CD4+ T cells and Foxp3+ CD25+ Tregs acutely 
home to the gut. The lack of a clear Foxp3+ CD25+ 
tTreg response suggests that the homeostatic regula-
tion of immune responses in the gut taking part from 
day to day is primarily handled by the MLN T cell 
pool and proliferation of already gut-associated 
tTregs.
The lack of long-term effects suggests that the 
MLN regulatory responses are not maintained by 
high cell numbers or cytokine signals, and accord-
ingly, most interventions in the GM of mice 
resulting in permanently altered immunity have 
been performed during fetal life or in pre-wean-
ing pups.13,16 Also intervention right after wean-
ing induces a permanent immune modulation, 
implicating that the post-weaning phase is also 
important for immune system development.15 
Taken together, the above described results could 
narrow down the window for permanent immune 
modulation to the postnatal period including the 
immediate days after weaning. This is also the 
period when the immune system encounters a 
large load of unknown antigens. Another influ-
encing factor for long-term immune modulation 
might be how DSS treatment itself affects GM 
composition. A 1.5% DSS treatment in 5-week-
old mice induces a loss of species diversity, and it 
favors Gram-negative phyla acutely from day 1 
after treatment and long term to day 25  after 
treatment.23,71,72
Increased GM–host contact seems to induce 
some acute MLN adaptive responses as indicated 
by the increased expression of CD44, CD25, and 
CD314 on CD4+ T cells as well as CD218a and 
CD314 acutely on CD8+ T cells.4,73–75 We also 
observed long-term induction of CD218a on 
CD4+ T cells in the MLN in the 4% group. Earlier 
studies have shown that intestinal wall CD218a+ 
CD4+ T cells, which may be stimulated to release 
pro-inflammatory cytokines, are present in lym-
phoid aggregates of human Crohn’s disease 
patients, and in both human and mice, CD218a 
expressing CD4+ T cells are disposed to secrete 
IFN-γ if stimulated with IL-18.76,77 A possible 
mechanism could be less rigid thymic thymocyte 
selection processes, due to processes being accel-
erated by an increased peripheral T cell need dur-
ing active gut inflammation. This is supported by 
a study finding that colitis-derived thymic involu-
tion leads to negative selection failure, increasing 
the number of auto-reactive T cells in the periph-
ery and inducing a chronic inflammatory pheno-
type predisposing for autoimmune diseases.78 The 
observed increase in the relative fraction of 
mature SP thymocyte subsets may further support 
this.39,41
In conclusion, this study demonstrated that low-
dose DSS treatment in post-weaning 5-week-old 
BALB/c mice even in the absence of high-grade 
inflammation increased gut permeability leading 
to non-persisting generalized thymic involution 
including most thymocyte subsets. Also, acute and 
non-persisting MLN regulatory responses were 
induced as a relative increase in the Foxp3+ 
CD25+ Tregs in the gut-homing marker express-
ing CD4+ T cell pool. We showed no changes in 
total thymic Foxp3+ CD25+ tTreg thymocyte 
numbers, and thus, the thymus does not seem to 
play a major role in post-weaning GM–host con-
tact induced regulatory immunity, which in our 
study primarily was located to the gut.
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